#Norway #Oslo #Bladder Cancer #Photocure #health economics

New Health Economic Approach for Bladder Cancer

Photocure ASA, a prominent player in bladder cancer innovation, announced the publication of a groundbreaking study in The Journal of Medical Economics. This new methodology for health economics focuses on comparing the cost-effectiveness of two diagnostic technologies: Blue Light Cystoscopy (BLC) and Narrow Band Imaging (NBI). The purpose of this study is to provide insights into which technology is more economical for healthcare systems while effectively diagnosing bladder cancer.

Background and Significance

Bladder cancer remains a significant global health concern, being the 8th most prevalent cancer worldwide, particularly affecting men. With high recurrence rates, bladder cancer demands careful management and frequent monitoring, leading to substantial healthcare costs. In this context, evaluating diagnostic technologies like BLC and NBI for their cost-effectiveness is crucial for healthcare policymakers and providers alike.

Study Overview

The research evaluated a cost-utility model for BLC and NBI developed specifically for the Danish Treatment Council's health technology appraisal last year. The results indicate that BLC is not only effective but also cost-efficient compared to NBI when projected over the patient’s lifetime. The study illustrates the necessity of addressing the challenges posed by insufficient evidence in determining cost-effectiveness.

Innovative Methodology

The article titled Addressing the challenges of health economic modelling in the context of suboptimal evidence base - case study based on a comparison between photodynamic diagnosis and narrow band imaging in non-muscle invasive bladder cancer outlines a novel method that gathers, transforms, and interprets key data points from existing clinical trials. It allows for a responsible comparison between the two technologies despite some data gaps.

Dr. Jonathan Belsey, the lead author of the study, emphasized the importance of this methodological approach in ensuring that health authorities can make informed decisions about technology comparison. The findings suggest that BLC demonstrates a cost-effectiveness measure (ICER) of DKK 70,707 per Quality Adjusted Life Year (QALY), significantly below the conventional threshold for cost-effectiveness.

Outcomes and Implications

The study further aligns with previous meta-analyses indicating that BLC is superior in reducing the recurrence rates of bladder tumors. This enhances the argument for adopting BLC in clinical settings, promising long-term savings and improved patient outcomes. Researchers found that the evidence base for BLC is robust, with extensive follow-up data from various randomized trials, in comparison to NBI, which has a narrower evidence spectrum.

Anders Neijber, Chief Medical Officer for Photocure, noted that these findings bolster the case for BLC as a more effective technology not just from an outcome perspective but also from an economic standpoint.

Conclusion

The emergence of this new health economic methodology is expected to facilitate better understanding and comparison of diagnostic technologies amidst data limitations. With bladder cancer's high healthcare costs and the pressing need for timely and effective treatment, the innovative approach provided in this study marks a significant advancement for health technology assessment. This research not only enhances the knowledge base but also contributes significantly to the ongoing discourse on how to manage bladder cancer effectively and economically.

To read more about the study and its findings, follow this link: Full Publication